Larvol Delta - Phase-II-Study-to-Evaluate-Safety-and-Efficacy-of-CB103-With-Venetoclax-in-Adolescent-and-Young-Adult-Patients-With-RelapsedRefractory-TALL-or-TLBL

CB-103 - Cellestia Biotech

Venclexta (venetoclax) - Roche, AbbVie

http://clinicaltrials.gov/ct2/show/NCT05464836

Jul 19, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next